1nkemia IUCT Group SA
MAD:IKM
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| ES |
|
1nkemia IUCT Group SA
MAD:IKM
|
7.9m EUR |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
385B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.8B USD |
Loading...
|
Market Distribution
| Min | -2 951.2% |
| 30th Percentile | 4.9% |
| Median | 12% |
| 70th Percentile | 19.6% |
| Max | 143.7% |
Other Profitability Ratios
1nkemia IUCT Group SA
Glance View
1nKemia IUCT Group SA engages in the research and development activities related to pharmaceutical, chemical, and biotechnology industries. The company is headquartered in Mollet Del Valles, Barcelona. The company went IPO on 2012-12-21. The firm provides products and services for chemical, pharmaceutical, biopharmaceutical, life science and related industry. The Company’s activity is related to the generation, promotion, development and sale of products and services. The firm transforms its knowledge and know-how into a pipeline of products, processes, services and technological platforms. Its solutions are specialized, integrated and protected by patents. The main areas of expertise are related to drugs development, industrial biotechnology and green chemistry. The firm has a number of subsidiaries, including IUCT SA and IUCT Empren SL.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
Over the last 3 years, 1nkemia IUCT Group SA’s Operating Margin has increased from -118.6% to 46.7%. During this period, it reached a low of -135.4% on Dec 31, 2016 and a high of 46.7% on Jan 31, 2019.